Zobrazeno 1 - 10
of 437
pro vyhledávání: '"S, Glisson"'
Autor:
Charles Lu, Mehmet Altan, Apar Pataer, Tina Cascone, Annikka Weissferdt, Jianjun Zhang, Boris Sepesi, Ara A Vaporciyan, Marcelo V Negrao, Hai T Tran, Stephen G Swisher, John V Heymach, Don L Gibbons, Brett W Carter, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Wayne L Hofstetter, J Jack Lee, Bonnie S Glisson, Myrna C B Godoy, Garrett L Walsh, Jia Wu, Humam Kadara, George R Blumenschein, Heather Y Lin, Nicolas Zhou, William N William, Cheuk H Leung, Frank V Fossella, Anne S Tsao, Jonathan M Kurie, Lauren A Byers, Reza J Mehran, David C Rice, Luisa M Solis Soto
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the efficacy of ne
Externí odkaz:
https://doaj.org/article/6cabe896ecc5458b81684d743e2ba8f9
ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response
Autor:
Jing Wang, Lei Feng, Qi Wang, Erminia Massarelli, Renata Ferrarotto, Michael A Curran, Jack Lee, Ignacio Wistuba, Cornelis J M Melief, Bonnie S Glisson, Kimal Rajapakshe, Cristian Coarfa, William William, Luana Guimaraes de Sousa, Jaime Rodriguez Canales, Renee L Chin, Tomas Z Barrese, Faye M Johnson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background The combination of ISA101, a human papilloma virus (HPV) 16 peptide vaccine, and nivolumab showed a promising response rate of 33% in patients with incurable HPV-16+ cancer. Here we report long-term clinical outcomes and immune correlates
Externí odkaz:
https://doaj.org/article/34f47116ff354f21a698a6dbad44cf29
Autor:
Jianhua Zhang, Hao Xu, Alexandre Reuben, Brian Alexander, Jack Lee, Tina Cascone, Jianjun Zhang, Kyle G Mitchell, Marcelo V Negrao, Stephen G Swisher, John V Heymach, Don L Gibbons, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Anne Tsao, Chang-Jiun Wu, Vincent A Miller, Bonnie S Glisson, Karthikeyan Murugesan, Meagan Montesion, Garrett Frampton, Katja Schulze, Ilze Bara, Vincent Shen, Sylvia Hu, Dawen Sui, Michael E Goldberg, David S Barreto, Jacqulyne P Robichaux, Carl M Gay, Lingzhi Hong, Waree Rinsurongkawong, Vassiliki Papadimitrakopoulou, Gaurav Singal, Lee A Albacker, David Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. W
Externí odkaz:
https://doaj.org/article/deb634044c5641f5a4d7746a8b39b598
Autor:
Renata Ferrarotto, Luana G. Sousa, Lei Feng, Frank Mott, George Blumenschein, Mehmet Altan, Diana Bell, Flavia Bonini, Kaiyi Li, Mario L. Marques-Piubelli, Eduardo A. Dal Lago, Jason J. Johnson, Yoshitsugu Mitani, Myrna Godoy, Anna Lee, Michael Kupferman, Ehab Hanna, Bonnie S. Glisson, Yasir Elamin, Adel El-Naggar
Publikováno v:
Journal of Clinical Oncology. 41:2843-2851
PURPOSE We conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). PATIENTS AND METHODS Eligible patients had R/M ACC with p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a2e3fd4daf39eb0ff4de2c56ccbb52d
https://doi.org/10.1200/jco.22.02221
https://doi.org/10.1200/jco.22.02221
Autor:
Tina Cascone, Cheuk H. Leung, Annikka Weissferdt, Apar Pataer, Brett W. Carter, Myrna C. B. Godoy, Hope Feldman, William N. William, Yuanxin Xi, Sreyashi Basu, Jing Jing Sun, Shalini S. Yadav, Frank R. Rojas Alvarez, Younghee Lee, Aditya K. Mishra, Lili Chen, Monika Pradhan, Haiping Guo, Ansam Sinjab, Nicolas Zhou, Marcelo V. Negrao, Xiuning Le, Carl M. Gay, Anne S. Tsao, Lauren Averett Byers, Mehmet Altan, Bonnie S. Glisson, Frank V. Fossella, Yasir Y. Elamin, George Blumenschein, Jianjun Zhang, Ferdinandos Skoulidis, Jia Wu, Reza J. Mehran, David C. Rice, Garrett L. Walsh, Wayne L. Hofstetter, Ravi Rajaram, Mara B. Antonoff, Junya Fujimoto, Luisa M. Solis, Edwin R. Parra, Cara Haymaker, Ignacio I. Wistuba, Stephen G. Swisher, Ara A. Vaporciyan, Heather Y. Lin, Jing Wang, Don L. Gibbons, J. Jack Lee, Nadim J. Ajami, Jennifer A. Wargo, James P. Allison, Padmanee Sharma, Humam Kadara, John V. Heymach, Boris Sepesi
Publikováno v:
Nature Medicine. 29:593-604
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc4d46457c34ffd4bc56a0716fe62bc7
https://doi.org/10.1038/s41591-022-02189-0
https://doi.org/10.1038/s41591-022-02189-0
Autor:
Faye M. Johnson, Bonnie S. Glisson, Jeffrey N. Myers, John V. Heymach, Katherine Stemke-Hale, You-Hong Fan, Lixia Diao, Shaohua Peng, Gordon B. Mills, Patrick Kwok Shing Ng, Lauren A. Byers, Tuhina Mazumdar
Supplementary figure 3. Correlation of PI3K mutation, amplification, PI3K score, and mTOR score with sensitivity to GDC0941
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65747d7306da0aaa210f0532f9f6cdcc
https://doi.org/10.1158/1535-7163.22502643.v1
https://doi.org/10.1158/1535-7163.22502643.v1
Autor:
John V. Heymach, John D. Minna, John N. Weinstein, Kevin R. Coombes, Gordon B. Mills, Scott M. Lippman, Luc Girard, Ignacio I. Wistuba, Neda Kalhor, Bonnie S. Glisson, Stephanie Weber, James Welsh, Vikas Bhardwaj, Praveen Tumula, Boris Duchemann, Wenbin Liu, Li Shen, Fatemeh Masrorpour, Lixia Diao, You Hong Fan, Michael Peyton, Uma Giri, John Yordy, Pierre Saintigny, Junya Fujimoto, Monique B. Nilsson, Jing Wang, Lauren Averett Byers
Small cell lung cancer (SCLC) is an aggressive malignancy distinct from non–small cell lung cancer (NSCLC) in its metastatic potential and treatment response. Using an integrative proteomic and transcriptomic analysis, we investigated molecular dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::199579cf247a86707b6f73da44e9cb80
https://doi.org/10.1158/2159-8290.c.6545709.v1
https://doi.org/10.1158/2159-8290.c.6545709.v1
Autor:
Lauren A. Byers, Don L. Gibbons, John V. Heymach, Julien Sage, Ignacio I. Wistuba, Bonnie S. Glisson, Jing Wang, Yongbin Yang, Youhong Fan, Lerong Li, Lixia Diao, Thuyen Nguyen, Sandra Cristea, Junya Fujimoto, Naoto Morikawa, Carminia M. Della Corte, Limo Chen, B. Leticia Rodriguez, Triparna Sen
This file contains supplementary materials and methods; figures and figure legends and Tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c4cd4391799b86995830b41b6be94ea
https://doi.org/10.1158/2159-8290.22532635.v1
https://doi.org/10.1158/2159-8290.22532635.v1
Autor:
Faye M. Johnson, Bonnie S. Glisson, Jeffrey N. Myers, John V. Heymach, Katherine Stemke-Hale, You-Hong Fan, Lixia Diao, Shaohua Peng, Gordon B. Mills, Patrick Kwok Shing Ng, Lauren A. Byers, Tuhina Mazumdar
Supplementary Tables and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405bd9c349e3422ed77fda4437f55a8a
https://doi.org/10.1158/1535-7163.22502652
https://doi.org/10.1158/1535-7163.22502652
Autor:
Faye M. Johnson, Bonnie S. Glisson, Jeffrey N. Myers, John V. Heymach, Katherine Stemke-Hale, You-Hong Fan, Lixia Diao, Shaohua Peng, Gordon B. Mills, Patrick Kwok Shing Ng, Lauren A. Byers, Tuhina Mazumdar
Supplementary figure 2. Representative FISH data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::026b7589fd343a485807ecd5198ee4db
https://doi.org/10.1158/1535-7163.22502646
https://doi.org/10.1158/1535-7163.22502646